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ABSTRACT 
 
The underlying mechanism and determinants of inhibitor formation in approximately 
30% haemophilia A and 5% haemophilia B patients are not fully understood. A large 
amount of the data on immune responses against FVIII and FIX is from animal 
models. Studies investigating cytokines in haemophilia are very limited and 
fragmentary, and the classification of hemophilia patients according to their factor 
activity levels has been observed to be inconsistent. The current study aims to find the 
associations between factor levels, clinical phenotype, cytokine profiles and 
polymorphisms in the IL-10 gene promoter of haemophilia A and B patients with and 
without inhibitors. This may give more insight into the pathophysiology of 
haemophilia, help improve the understanding of the pathogenic mechanisms that 
underlie inhibitor development, and facilitate new diagnostic and therapeutic 
strategies for haemophilia.  
Haemophilia A and B patients with and without inhibitors were enrolled in the 
current study. Forty (40) patients from the Charlotte Maxeke Johannesburg Academic 
Hospital Haemophilia Comprehensive Care Centre (CMJAH-HCCC) were randomly 
selected. An equal number of frequent bleeders and infrequent bleeders were 
recruited. Frequent bleeders were defined as those patients with 2 or more bleeding 
episodes per month on three consecutive months. Bleeding frequency was evaluated 
on the patient’s bleeding charts.  
 v
FVIII and FIX activity levels of all patients were measured using the Dade Behring 
Sysmex CA-7000 coagulation analyzer, and information on each patient’s bleeding 
episodes was obtained from the haemophilia bleeding charts. The inhibitor status of 
all patients was evaluated using the Bethesda inhibitor assay. IL-1β, IL-6 and TNF-α 
were analyzed using an ELISA kit method. IL-2, IL-4, IL-10 and IFN-γ were 
analyzed using the CBA Human TH1/TH2 Cytokine Kit. DNA was extracted using 
the Nucleon BACC3 from Amersham Biosciences. Polymorphisms in the IL-10 gene 
promoter region were analyzed using PCR. The Statistica Release 8 statistics package 
was used for statistical analysis.   
 
The present study population showed significant discrepancies in the theoretic 
classification of haemophilia patients. Severe haemophilia patients had significantly 
higher levels of IL-6 than the mild/moderate group and biochemical classification 
correlated positively with IL-6. IL-6 was also the only significant predictor of 
biochemical classification. IL-1β and IL-4 was found to be significantly higher in the 
mild/moderate group than in the severe group. There were no significant differences 
in the levels of IL-2, IL-10, and IFNγ between the mild/moderate and severe groups 
and between patients with inhibitors and without inhibitors. There were also no 
differences in the cytokine profiles of low and high responders. 
No significant differences were found between cytokine profiles of frequent and 
infrequent bleeders. IL-6 and TNF-α were found to be significantly higher in patients 
with inhibitors than in haemophilia patients without inhibitors. IL-6 and IL-1β were 
 vi
the only significant predictors of the inhibitor status of haemophilia patients. 
Haemophilia severity and race were found to be significant risk factors for inhibitor 
development. A 150 bp allele of the IL-10 promoter region with the microsattelite 
marker was observed in patients with and without inhibitors as well as the healthy 
controls. The 150 bp allele was also observed in both black and white subjects. 
 
Large phenotypic heterogeneity exists in haemophilia patients. The pro-inflammatory 
cytokines IL-6 and IL-1β together with IL-4 may be involved in determining the 
biochemical severity of haemophilia. IL-6 was the only cytokine in this study found 
to be a significant predictor of bleeding frequency. The study results also suggest that 
IL-6 and IL-1β may be involved in the production of antibodies against infused factor 
in patients with inhibitors.  
The presence of a 150 bp allele of the highly polymorphic IL-10 promoter region in 
patients with and without inhibitors as well as the healthy controls suggests that, 
polymorphisms in this gene do not influence inhibitor development in this population. 
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